With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARα) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Given that PPARα expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, blood pressure regulation, and the renin-angiotensin aldosterone system, PPARα likely influences the development and pathogenesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. These findings suggest that PPARα may become an important therapeutic target for treating diabetic renal complications.

Citations

Citations to this article as recorded by  

• The Proteome of Circulating Large Extracellular Vesicles in Diabetes and Hypertension
  Akram Abolbaghaei, Maddison Turner, Jean-François Thibodeau, Chet E. Holterman, Christopher R. J. Kennedy, Dylan Burger
  International Journal of Molecular Sciences.2023; 24(5): 4930.     CrossRef
• Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway
  Laongdao Thongnak, Nattavadee Pengrattanachot, Sasivimon Promsan, Nichakorn Phengpol, Prempree Sutthasupha, Krit Jaikumkao, Anusorn Lungkaphin
  Archives of Pharmacal Research.2023; 46(5): 408.     CrossRef
• A comprehensive insight into the molecular and cellular mechanisms of the effects of Propolis on preserving renal function: a systematic review
  Paniz Anvarifard, Maryam Anbari, Alireza Ostadrahimi, Mohammadreza Ardalan, Zohreh Ghoreishi
  Nutrition & Metabolism.2022;[Epub]     CrossRef
• APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice
  Eun Soo Lee, Hong Min Kim, Sun Hee Lee, Kyung Bong Ha, Yoon Soo Bae, Soo Jin Lee, Sung Hwan Moon, Eun Young Lee, Ji-Hye Lee, Choon Hee Chung
  Free Radical Biology and Medicine.2020; 161: 92.     CrossRef
• Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
  Xiaomeng Sun, Jia Liu, Guang Wang
  Lipids in Health and Disease.2020;[Epub]     CrossRef
• AMPK allostery: A therapeutic target for the management/treatment of diabetic nephropathy
  Kehinde Sulaimon Ayinde, Olamide Tosin Olaoba, Boyenle Ibrahim, Du Lei, Qian Lu, Xiaoxing Yin, Temitope Isaac Adelusi
  Life Sciences.2020; 261: 118455.     CrossRef
• Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor
  Ravi Shankar Singh, Dharmendra Kumar Chaudhary, Aradhana Mohan, Praveen Kumar, Chandra Prakash Chaturvedi, Carolyn M. Ecelbarger, Madan M. Godbole, Swasti Tiwari
  Scientific Reports.2016;[Epub]     CrossRef
• Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury
  Yong Yang, Ting Bai, You-Li Yao, De-Quan Zhang, Yan-Ling Wu, Li-Hua Lian, Ji-Xing Nan
  Toxicology Letters.2016; 262: 80.     CrossRef
• Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan
  Makoto Harada, Yuji Kamijo, Takero Nakajima, Koji Hashimoto, Yosuke Yamada, Hisashi Shimojo, Frank J. Gonzalez, Toshifumi Aoyama
  Clinical Science.2016; 130(21): 1969.     CrossRef
• Anthocyanin-rich Seoritae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice
  Eun Sil Koh, Ji Hee Lim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Bum Soon Choi, Hye Won Kim, Seong Yeon Hwang, Sae Woong Kim, Cheol Whee Park, Yoon Sik Chang
  Journal of Translational Medicine.2015;[Epub]     CrossRef
• Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives
  Cheol Whee Park
  Diabetes & Metabolism Journal.2014; 38(4): 252.     CrossRef
• Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
  Marijn M. Speeckaert, Céline Vanfraechem, Reinhart Speeckaert, Joris R. Delanghe
  Ageing Research Reviews.2014; 14: 1.     CrossRef
• Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats
  Pitchai Balakumar, Rajavel Varatharajan, Ying Hui Nyo, Raja Renushia, Devarajan Raaginey, Ann Nah Oh, Shaikh Sohrab Akhtar, Mani Rupeshkumar, Karupiah Sundram, Sokkalingam A. Dhanaraj
  Pharmacological Research.2014; 90: 36.     CrossRef
• Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy
  Supriya Kadian, Nanjaian Mahadevan, Pitchai Balakumar
  European Journal of Pharmacology.2013; 698(1-3): 388.     CrossRef
• Age-Associated Molecular Changes in the Kidney in Aged Mice
  Ji Hee Lim, Eun Nim Kim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Hyung Wook Kim, Chul Woo Yang, Yong-Soo Kim, Yoon Sik Chang, Cheol Whee Park, Bum Soon Choi
  Oxidative Medicine and Cellular Longevity.2012; 2012: 1.     CrossRef
• Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease
  Rikki M. Tanner, Todd M. Brown, Paul Muntner
  Current Hypertension Reports.2012; 14(2): 152.     CrossRef